College of Natural Resources & Sciences
Gene editing with CRISPR/Cas9 and AAVs has been a modern technology that has greatly influenced biological sciences. Coupling the editing technology of CRISPR and AAVs could lead to treating the underlying causes of pulmonary arterial hypertension(PAH). PAH is a progressive disease in your lungs that causes vasoconstriction and decreased blood flow, which can lead to heart failure. Placing a stent in the pulmonary artery, with endothelial cells engrafted on it, that overexpresses the important regulatory factors eNOS and VEGF, may lead to an increase in reendothelialization and vasodilation of the pulmonary artery.